Pre-operative beta-blocker therapy does not affect short-term mortality after esophageal resection for cancer.
Adolescent
Adrenergic beta-Antagonists
/ therapeutic use
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Esophageal Neoplasms
/ mortality
Esophagus
Female
Humans
Infant
Infant, Newborn
Male
Middle Aged
Postoperative Complications
/ epidemiology
Retrospective Studies
Sweden
/ epidemiology
Young Adult
Beta-blocker
Beta-blocker in surgery
Esophageal cancer
Mortality
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
22 Dec 2020
22 Dec 2020
Historique:
received:
08
09
2020
accepted:
15
12
2020
entrez:
23
12
2020
pubmed:
24
12
2020
medline:
15
1
2021
Statut:
epublish
Résumé
It has been postulated that the hyperadrenergic state caused by surgical trauma is associated with worse outcomes and that β-blockade may improve overall outcome by downregulation of adrenergic activity. Esophageal resection is a surgical procedure with substantial risk for postoperative mortality. There is insufficient data to extrapolate the existing association between preoperative β-blockade and postoperative mortality to esophageal cancer surgery. This study assessed whether preoperative β-blocker therapy affects short-term postoperative mortality for patients undergoing esophageal cancer surgery. All patients with an esophageal cancer diagnosis that underwent surgical resection with curative intent from 2007 to 2017 were retrospectively identified from the Swedish National Register for Esophagus and Gastric Cancers (NREV). Patients were subdivided into β-blocker exposed and unexposed groups. Propensity score matching was carried out in a 1:1 ratio. The outcome of interest was 90-day postoperative mortality. A total of 1466 patients met inclusion criteria, of whom 35% (n = 513) were on regular preoperative β-blocker therapy. Patients on β-blockers were significantly older, more comorbid and less fit for surgery based on their ASA score. After propensity score matching, 513 matched pairs were available for analysis. No difference in 90-day mortality was detected between β-blocker exposed and unexposed patients (6.0% vs. 6.6%, p = 0.798). Preoperative β-blocker therapy is not associated with better short-term survival in patients subjected to curative esophageal tumor resection.
Sections du résumé
BACKGROUND
BACKGROUND
It has been postulated that the hyperadrenergic state caused by surgical trauma is associated with worse outcomes and that β-blockade may improve overall outcome by downregulation of adrenergic activity. Esophageal resection is a surgical procedure with substantial risk for postoperative mortality. There is insufficient data to extrapolate the existing association between preoperative β-blockade and postoperative mortality to esophageal cancer surgery. This study assessed whether preoperative β-blocker therapy affects short-term postoperative mortality for patients undergoing esophageal cancer surgery.
METHODS
METHODS
All patients with an esophageal cancer diagnosis that underwent surgical resection with curative intent from 2007 to 2017 were retrospectively identified from the Swedish National Register for Esophagus and Gastric Cancers (NREV). Patients were subdivided into β-blocker exposed and unexposed groups. Propensity score matching was carried out in a 1:1 ratio. The outcome of interest was 90-day postoperative mortality.
RESULTS
RESULTS
A total of 1466 patients met inclusion criteria, of whom 35% (n = 513) were on regular preoperative β-blocker therapy. Patients on β-blockers were significantly older, more comorbid and less fit for surgery based on their ASA score. After propensity score matching, 513 matched pairs were available for analysis. No difference in 90-day mortality was detected between β-blocker exposed and unexposed patients (6.0% vs. 6.6%, p = 0.798).
CONCLUSION
CONCLUSIONS
Preoperative β-blocker therapy is not associated with better short-term survival in patients subjected to curative esophageal tumor resection.
Identifiants
pubmed: 33353542
doi: 10.1186/s12893-020-01017-x
pii: 10.1186/s12893-020-01017-x
pmc: PMC7754575
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
333Références
Ann Surg. 2002 Nov;236(5):643-8
pubmed: 12409671
Br J Surg. 2019 Mar;106(4):477-483
pubmed: 30259967
Obes Surg. 2020 Jan;30(1):139-145
pubmed: 31346982
Am J Surg. 1997 Jun;173(6):472-8
pubmed: 9207157
N Engl J Med. 2005 Jul 28;353(4):349-61
pubmed: 16049209
JPEN J Parenter Enteral Nutr. 2013 Sep;37(5 Suppl):21S-9S
pubmed: 24009246
Dis Esophagus. 2018 May 1;31(5):
pubmed: 29211841
J Am Coll Cardiol. 2004 Sep 1;44(5):e213-310
pubmed: 15337239
Ann Intern Med. 2011 Apr 19;154(8):523-8
pubmed: 21502650
J Thorac Dis. 2019 Apr;11(Suppl 5):S702-S706
pubmed: 31080647
J Trauma. 2008 Apr;64(4):1061-8
pubmed: 18404076
Lancet. 2008 May 31;371(9627):1839-47
pubmed: 18479744
CMAJ. 2005 Sep 13;173(6):627-34
pubmed: 16157727
JAMA. 2002 Mar 20;287(11):1435-44
pubmed: 11903031
Arch Surg. 2012 May;147(5):467-73
pubmed: 22249847
Lancet. 2017 Nov 25;390(10110):2383-2396
pubmed: 28648400
Ann Surg. 2020 Jan;271(1):140-146
pubmed: 30048321
N Engl J Med. 1996 Dec 5;335(23):1713-20
pubmed: 8929262
Ann Surg. 2012 Feb;255(2):216-21
pubmed: 22241289
BMJ Open. 2020 Jul 7;10(7):e036164
pubmed: 32641361
Br J Surg. 2016 Sep;103(10):1326-35
pubmed: 27467590
PLoS One. 2017 Mar 28;12(3):e0174382
pubmed: 28350805
J Am Coll Cardiol. 2017 Oct 31;70(18):2278-2289
pubmed: 29073957
J Am Coll Cardiol. 2014 Dec 9;64(22):e77-137
pubmed: 25091544
Cochrane Database Syst Rev. 2019 Sep 26;9:CD013438
pubmed: 31556094
Br J Anaesth. 2000 Jul;85(1):109-17
pubmed: 10927999
Surg Clin North Am. 2012 Oct;92(5):1299-313
pubmed: 23026283
Ann Surg. 2001 Mar;233(3):338-44
pubmed: 11224620
Anesth Analg. 2007 Jan;104(1):27-41
pubmed: 17179240